<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>T. Moyo | Michael Schomaker</title>
    <link>https://MichaelSchomaker.github.io/authors/t.-moyo/</link>
      <atom:link href="https://MichaelSchomaker.github.io/authors/t.-moyo/index.xml" rel="self" type="application/rss+xml" />
    <description>T. Moyo</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Wed, 25 Nov 2020 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://MichaelSchomaker.github.io/images/icon_hue888863bcf6448bbe1c2d7b1880687e8_12435_512x512_fill_lanczos_center_3.png</url>
      <title>T. Moyo</title>
      <link>https://MichaelSchomaker.github.io/authors/t.-moyo/</link>
    </image>
    
    <item>
      <title>HIV-1 Subtype C Tier 3 Viruses Have Increased Infectivity Compared to Tier 2 Viruses</title>
      <link>https://MichaelSchomaker.github.io/publication/2020-10-01-hiv1_subtype/</link>
      <pubDate>Wed, 25 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://MichaelSchomaker.github.io/publication/2020-10-01-hiv1_subtype/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Anti-V3-Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2-Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency</title>
      <link>https://MichaelSchomaker.github.io/publication/2015-01-01_anti-v3-glycan_and_a/</link>
      <pubDate>Thu, 01 Jan 2015 00:00:00 +0000</pubDate>
      <guid>https://MichaelSchomaker.github.io/publication/2015-01-01_anti-v3-glycan_and_a/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
